hematology

Zomacta Tablets (Eltrombopag Olamine Tablets) – Product Description Zomacta Tablets contain Eltrombopag Olamine, a prescription medicine used to increase platelet counts in patients with certain blood disorders. It belongs to the thrombopoietin receptor agonist (TPO-RA) class and works by stimulating the bone marrow to produce more platelets, helping reduce the risk of bleeding associated with low platelet levels. Zomacta is commonly prescribed for patients with chronic immune thrombocytopenia (ITP) who have not responded adequately to other treatments. It is also indicated for severe aplastic anemia (SAA) and for the treatment of thrombocytopenia associated with chronic hepatitis C, allowing eligible patients to initiate and maintain antiviral therapy under specialist supervision. Active Ingredient Eltrombopag Olamine Dosage Form Oral Tablets Therapeutic Indications Chronic Immune Thrombocytopenia (ITP) Severe Aplastic Anemia (SAA) Thrombocytopenia Associated with Chronic Hepatitis C Other approved indications as determined by the treating physician How It Works Eltrombopag binds to and activates the thrombopoietin (TPO) receptor on bone marrow cells, stimulating the production of platelets. Increased platelet counts help reduce the risk of bleeding in eligible patients with thrombocytopenia. Key Features Increases platelet production through TPO receptor stimulation Oral tablet for convenient daily administration Effective treatment option for chronic ITP and severe aplastic anemia Helps manage low platelet counts under specialist supervision Manufactured according to stringent pharmaceutical quality standards Storage Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children. Note: Zomacta Tablets (Eltrombopag Olamine) are prescription-only medicines and should be used only under the supervision of a qualified hematologist or physician. Regular monitoring of platelet counts, liver function, and complete blood counts is recommended during treatment.